CO FOUNDER & MANAGING PARTNER AUVEN THERAPEUTICS
Business
Stephen Evans-Freke is Co-Founder and Managing General Partner of Auven Therapeutics, a global private equity fund based in St. Thomas, US Virgin Islands, with offices in Europe, Bermuda and the United States. The company acquires and invests in drug development programs worldwide.
Since leaving Wall Street in 1990 as a leading life science and technology banker, Mr. Evans-Freke has founded or co-founded a series of companies in biotechnology and other industries, including…
ADC Therapeutics
Co-Founder and Director 2012 – present. A Swiss-based biotech company focused on break-through cancer therapies; with a private company valuation of $1.3 billion, it ranks as one of few ‘unicorn’ private biotechnology companies in Europe
CIBUS Global LLC
Founder and Chairman 2001-2010 – the first non-GMO agri-biotech company, to be taken public by Morgan Stanley in 2019
SUGEN
Founder, Chairman and CEO 1991-1999 – A pharmaceutical industry leader in a novel class of cancer drugs which was taken public by Morgan Stanley in 1995 and sold to Pharmacia Corp for $720 million in 1999
Selectide Corporation
Founder, Chairman and lead investor 1990-1994 – a pioneering combinatorial chemistry company; sold to Bayer in 1994
Royalty Pharma
Co-Founder, Managing Partner 1996-2004 – the first aggregator of pharmaceutical royalty assets with a portfolio now valued in excess of $15 billion
Stephen Evans-Freke has played a significant role in financing the development of numerous biotechnology therapeutic drugs, including the following:
| Product | Indication | Company | Peak Sales | Launch |
|---|---|---|---|---|
| Protropin/Nutropin | Growth disorders | Genentech | $400mm+ | 1985 |
| Activase | Heart Attack/Stroke | Genentech | +/-$2.5bn | 1987 |
| Avastin | Cancer | Genentech | $7bn | 2004 |
| Neupogen | Cancer | AMGEN | $3.9bn | 1991 |
| Remicade | Autoimmune disorders | Centocor/J&J | $5.6bn | 1998 |
| Embril | Rheumatoid Arthritis | Immunex/AMGEN | $5.9bn | 1998 |
| Sutent | Cancer | SUGEN/Pfizer | $1.1bn | 2006 |
| Obizur | Hemophilia | Inspiration/Shire | $3-500mm Projected | 2014 |
| Cequa | Dry Eye | Auven/Sun | $700mm+ | 2019 |
| ADCT-402 | Blood cancers | ADC Therapeutics | $1.5bn Projected | 2020-21E |
| ADCT-301 | Blood cancers | ADC Therapeutics | $1.2bn Projected | 2021E |
